Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

IART earnings analysis

Filed October 23, 2026 · Our reading of the company's report

The latest report

Integra delivered $411.2 million of Q3 revenue, down approximately 1.9% sequentially but up approximately 2.3% year over year, while GAAP diluted EPS improved to $0.19 from $0.06 in Q2 and $(0.07) a year earlier.…

Read full summary

Integra delivered $411.2 million of Q3 revenue, down approximately 1.9% sequentially but up approximately 2.3% year over year, while GAAP diluted EPS improved to $0.19 from $0.06 in Q2 and $(0.07) a year earlier. Operating cash flow was $96.0 million, but Cincinnati disruption and Tissue Reconstruction weakness remained headwinds. Management maintained full-year 2026 guidance of $1.634 billion-$1.654 billion in revenue and $2.30-$2.40 of adjusted EPS, leaving the overall filing sentiment neutral.

Read the original on SEC.gov

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish May 2026 Oct 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

Reported figures

Earnings per share
$0.19

What stood out

  • Revenue grew year over year

    Revenue was $411.2 million, down from $419 million in Q2 2026 but up from $402 million in Q3 2025, representing sequential contraction of approximately 1.9% and year-over-year growth of approximately 2.3%.

  • GAAP EPS improved materially

    GAAP diluted EPS was $0.19, improving from $0.06 in Q2 2026 and a $(0.07) loss in Q3 2025.

  • Strong quarterly cash generation

    Operating cash flow was $96.0 million for the quarter, supporting liquidity despite the Cincinnati disruption and weaker Tissue Reconstruction results.

  • Full-year outlook maintained

    Full-year 2026 revenue guidance remained $1.634 billion-$1.654 billion and adjusted EPS guidance remained $2.30-$2.40.

What to watch

  • Floating-rate debt exposure

    Debt remains exposed to floating-rate movements: the company had $900.0 million of interest-rate swap notional outstanding, while a 100-basis-point rate change would affect annual interest expense on the unhedged debt portion by $9.5 million.

  • Interest-rate sensitivity

    The company disclosed that a 100-basis-point rate movement on cash and cash equivalents at September 30, 2026 would change annual interest income by approximately $2.5 million; short-term investments add another $0.6 million of annual sensitivity.

  • No material risk-factor update

    The filing states there were no material changes to the risk factors in the December 31, 2025 Form 10-K; therefore, no new quantified risk-factor change was identified in this 10-Q.

Management's outlook

Full-year 2026 revenue and adjusted EPS outlook was maintained at $1.634-$1.654 billion and $2.30-$2.40, respectively. Q4 revenue guidance is $413 million-$433 million and adjusted EPS guidance is $0.61-$0.71; full-year operating cash flow is expected at approximately $190 million-$200 million.

Earlier filings 2

10-Q · July 29, 2026

Integra delivered modest Q2 revenue growth of 0.8% to $418.761 million, while GAAP EPS improved to $0.06 from a $6.31 loss per share in the prior-year quarter, chiefly because the 2025 period included a $511.4 million…

10-Q · May 5, 2026

Integra LifeSciences reported Q1 2026 results with revenues of $391.9 million, up from $382.7 million year-over-year, and adjusted EPS of $0.54, an increase from $0.41. Management highlighted operational improvements…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.